open access

Vol 13, No 5 (2017)
Review paper
Published online: 2017-11-15
Get Citation

Molecularly targeted therapies in advanced renal-cell carcinoma — optimisation of first-line therapy

Jakub Żołnierek
DOI: 10.5603/OCP.2017.0024
·
Oncol Clin Pract 2017;13(5):216-219.

open access

Vol 13, No 5 (2017)
REVIEW ARTICLES
Published online: 2017-11-15

Abstract

Currently, systemic treatment of advanced renal-cell carcinoma is based on targeted therapy, mostly including
tyrosine kinases inhibitors with anti-VEGF activity. The achieved effect is cytostatic. The systemic treatment is
conducted in a sequential manner. The choice of the first-line treatment agent is crucial but may be problematic
due to the lack of molecular predictors. Sunitinib and pazopanib are the tyrosine kinases inhibitors of choice in
the first-line therapy. They differ in terms of their selectivity in cellular kinome inhibition. In effect, they also have
a different toxicity profile and influence on the patient’s quality of life during the therapy. These differences are
important when choosing the optimal treatment. The superiority of the both drugs over one another has been
discussed for years. The article is a review of this issue.

Abstract

Currently, systemic treatment of advanced renal-cell carcinoma is based on targeted therapy, mostly including
tyrosine kinases inhibitors with anti-VEGF activity. The achieved effect is cytostatic. The systemic treatment is
conducted in a sequential manner. The choice of the first-line treatment agent is crucial but may be problematic
due to the lack of molecular predictors. Sunitinib and pazopanib are the tyrosine kinases inhibitors of choice in
the first-line therapy. They differ in terms of their selectivity in cellular kinome inhibition. In effect, they also have
a different toxicity profile and influence on the patient’s quality of life during the therapy. These differences are
important when choosing the optimal treatment. The superiority of the both drugs over one another has been
discussed for years. The article is a review of this issue.

Get Citation

Keywords

renal-cell carcinoma; molecularly targeted therapy; tyrosine kinase inhibitors; sunitinib; pazopanib

About this article
Title

Molecularly targeted therapies in advanced renal-cell carcinoma — optimisation of first-line therapy

Journal

Oncology in Clinical Practice

Issue

Vol 13, No 5 (2017)

Article type

Review paper

Pages

216-219

Published online

2017-11-15

DOI

10.5603/OCP.2017.0024

Bibliographic record

Oncol Clin Pract 2017;13(5):216-219.

Keywords

renal-cell carcinoma
molecularly targeted therapy
tyrosine kinase inhibitors
sunitinib
pazopanib

Authors

Jakub Żołnierek

References (8)
  1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2): 115–124.
  2. Motzer R, Hutson T, Tomczak P, et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2009; 27(22): 3584–3590.
  3. Sternber CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28(6): 1061–1068.
  4. Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. E J Cancer. 2013; 49(6): 1287–1296.
  5. Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol. 2014; 32(14): 1412–1418.
  6. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013; 369(8): 722–731.
  7. Ruiz-Morales JM, Swierkowski M, Wells JC, et al. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Journal Cancer. 2015; 65: 102–108.
  8. Heng DYC, Choueiri TK, Rini BI, et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol. 2014; 25(1): 149–154.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl